Literature DB >> 25745830

Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future.

Yotam Levin1, Efrat Kochba, Ivan Hung, Richard Kenney.   

Abstract

Intradermal immunization has become a forefront of vaccine improvement, both scientifically and commercially. Newer technologies are being developed to address the need to reduce the dose required for vaccination and to improve the reliability and ease of injection, which have been major hurdles in expanding the number of approved vaccines using this route of administration. In this review, 7 y of clinical experience with a novel intradermal delivery device, the MicronJet600, which is a registered hollow microneedle that simplifies the delivery of liquid vaccines, are summarized. This device has demonstrated both significant dose-sparing and superior immunogenicity in various vaccine categories, as well as in diverse subject populations and age groups. These studies have shown that intradermal delivery using this device is safe, effective, and preferred by the subjects. Comparison with other intradermal devices and potential new applications for intradermal delivery that could be pursued in the future are also discussed.

Keywords:  AE, adverse event; BCG, Bacillus Calmette–Guérin; BD, Becton Dickinson; CDC, Center of Disease Control; DTP, diphtheria, pertussis and tetanus; EMEA, European Medicines Agency; FDA, Food and Drug Administration; GMT, geometric mean titer; HA, hemagglutinin; HBV, hepatitis B virus; HIV, Human immunodeficiency virus; HPV, human papilloma virus; ID, intradermal; IM, Intramuscular; IPV, inactivated polio vaccine; MEMS, Micro Electro Mechanical System; Mantoux; PPD, Purified protein derivative; SAGE, Strategic Advisory Group of Experts; SQ, subcutaneous; WHO, World Health Organization; dose-sparing; icddr,b, International Center for Diarrheal Disease Research, Bangladesh; immunogenicity; influenza vaccine; intradermal; microneedles; vaccine delivery; vaccine device

Mesh:

Substances:

Year:  2015        PMID: 25745830      PMCID: PMC4514308          DOI: 10.1080/21645515.2015.1010871

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  100 in total

1.  Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies.

Authors:  Devin V McAllister; Ping M Wang; Shawn P Davis; Jung-Hwan Park; Paul J Canatella; Mark G Allen; Mark R Prausnitz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-17       Impact factor: 11.205

2.  Quantitative and qualitative analysis of antibody response after dose sparing intradermal 2009 H1N1 vaccination.

Authors:  Ivan F N Hung; Yotam Levin; Kelvin K W To
Journal:  Vaccine       Date:  2011-12-27       Impact factor: 3.641

3.  Acceptance and opinions of Intanza/IDflu intradermal influenza vaccine in the Czech Republic and Turkey.

Authors:  Roman Prymula; Gaye Usluer; Serdar Altinel; Radka Sichova; Françoise Weber
Journal:  Adv Ther       Date:  2012-01-03       Impact factor: 3.845

4.  Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years: Randomized, controlled, phase III trial.

Authors:  Robert Arnou; Patrick Eavis; José-Ramon De Juanes Pardo; Arvydas Ambrozaitis; Marie-Pierre Kazek; Françoise Weber
Journal:  Hum Vaccin       Date:  2010-04-15

5.  Meeting of the Strategic Advisory Group of Experts on immunization, April 2012--conclusions and recommendations.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2012-05-25

6.  DNA tattoo vaccination: effect on plasmid purity and transfection efficiency of different topoisoforms.

Authors:  S G L Quaak; J H van den Berg; K Oosterhuis; J H Beijnen; J B A G Haanen; B Nuijen
Journal:  J Control Release       Date:  2009-07-04       Impact factor: 9.776

7.  Reduced-dose intradermal vaccination against hepatitis A with an aluminum-free vaccine is immunogenic and can lower costs.

Authors:  Chitsanu Pancharoen; Jutarat Mekmullica; Usa Thisyakorn; Songsri Kasempimolporn; Henry Wilde; Christian Herzog
Journal:  Clin Infect Dis       Date:  2005-10-13       Impact factor: 9.079

8.  Immunisation of 4-6 month old Gambian infants with Edmonston-Zagreb measles vaccine.

Authors:  H C Whittle; M G Rowland; G F Mann; W H Lamb; R A Lewis
Journal:  Lancet       Date:  1984-10-13       Impact factor: 79.321

9.  Priming after a fractional dose of inactivated poliovirus vaccine.

Authors:  Sonia Resik; Alina Tejeda; Roland W Sutter; Manuel Diaz; Luis Sarmiento; Nilda Alemañi; Gloria Garcia; Magilé Fonseca; Lai Heng Hung; Anna-Lea Kahn; Anthony Burton; J Mauricio Landaverde; R Bruce Aylward
Journal:  N Engl J Med       Date:  2013-01-31       Impact factor: 91.245

10.  DNA-vaccination via tattooing induces stronger humoral and cellular immune responses than intramuscular delivery supported by molecular adjuvants.

Authors:  Dana Pokorna; Ivonne Rubio; Martin Müller
Journal:  Genet Vaccines Ther       Date:  2008-02-07
View more
  25 in total

Review 1.  Immunogenicity, safety and tolerability of intradermal influenza vaccines.

Authors:  Ivan F N Hung; Kwok-Yung Yuen
Journal:  Hum Vaccin Immunother       Date:  2017-07-06       Impact factor: 3.452

2.  Minimally invasive method for the point-of-care quantification of lymphatic vessel function.

Authors:  Anna K Polomska; Steven T Proulx; Davide Brambilla; Daniel Fehr; Mathias Bonmarin; Simon Brändli; Mirko Meboldt; Christian Steuer; Tsvetina Vasileva; Nils Reinke; Jean-Christophe Leroux; Michael Detmar
Journal:  JCI Insight       Date:  2019-02-21

3.  Comparison of immunogenicity between intradermal and intramuscular injections of repeated annual identical influenza virus strains post-pandemic (2011-2012) in COPD patients.

Authors:  Benjamas Chuaychoo; Uraiwan Kositanont; Parichat Niyomthong; Nuttapol Rittayamai; Sorachai Srisuma; Kanokwan Rattanasaengloet; Walaiporn Wongsrisakunkaew; Julalux Thongam; Thaweesak Songserm
Journal:  Hum Vaccin Immunother       Date:  2019-11-26       Impact factor: 3.452

4.  Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature.

Authors:  Elena V Vassilieva; Haripriya Kalluri; Devin McAllister; Misha T Taherbhai; E Stein Esser; Winston P Pewin; Joanna A Pulit-Penaloza; Mark R Prausnitz; Richard W Compans; Ioanna Skountzou
Journal:  Drug Deliv Transl Res       Date:  2015-08       Impact factor: 4.617

Review 5.  Advances in Infectious Disease Vaccine Adjuvants.

Authors:  Jingyi Fan; Shengbin Jin; Lachlan Gilmartin; Istvan Toth; Waleed M Hussein; Rachel J Stephenson
Journal:  Vaccines (Basel)       Date:  2022-07-13

Review 6.  Non-transdermal microneedles for advanced drug delivery.

Authors:  KangJu Lee; Marcus J Goudie; Peyton Tebon; Wujin Sun; Zhimin Luo; Junmin Lee; Shiming Zhang; Kirsten Fetah; Han-Jun Kim; Yumeng Xue; Mohammad Ali Darabi; Samad Ahadian; Einollah Sarikhani; WonHyoung Ryu; Zhen Gu; Paul S Weiss; Mehmet R Dokmeci; Nureddin Ashammakhi; Ali Khademhosseini
Journal:  Adv Drug Deliv Rev       Date:  2019-12-16       Impact factor: 15.470

Review 7.  Emerging skin-targeted drug delivery strategies to engineer immunity: A focus on infectious diseases.

Authors:  Emrullah Korkmaz; Stephen C Balmert; Cara Donahue Carey; Geza Erdos; Louis D Falo
Journal:  Expert Opin Drug Deliv       Date:  2020-10-06       Impact factor: 8.129

Review 8.  Trends of microneedle technology in the scientific literature, patents, clinical trials and internet activity.

Authors:  Rohan S J Ingrole; Erkan Azizoglu; Maria Dul; James C Birchall; Harvinder S Gill; Mark R Prausnitz
Journal:  Biomaterials       Date:  2020-11-05       Impact factor: 12.479

9.  Vaccine delivery alerts innate immune systems for more immunogenic vaccination.

Authors:  Zhuofan Li; Yan Cao; Yibo Li; Yiwen Zhao; Xinyuan Chen
Journal:  JCI Insight       Date:  2021-04-08

10.  Insertion Process of Ceramic Nanoporous Microneedles by Means of a Novel Mechanical Applicator Design.

Authors:  Xavier H M Hartmann; Peter van der Linde; Erik F G A Homburg; Lambert C A van Breemen; Arthur M de Jong; Regina Luttge
Journal:  Pharmaceutics       Date:  2015-11-18       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.